BioSpace News Archive

Addex Therapeutics, a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced that it will issue its Q1 2023 financial results on Thursday, May 11, 2023.

argenx SE, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced its first quarter 2023 financial results and provided a business update.

Valneva SE reported its first quarter financial results ending March 31, 2023, and provided corporate updates.

AlzeCure Pharma AB announced that its interim report for the period January - March 2023 is now available on the company’s website.

PureTech Health plc, a clinical-stage biotherapeutics company noted that its Founded Entity, Akili, Inc., a leading digital medicine company, announced topline results of the STARS-ADHD-Adult clinical trial evaluating the efficacy and safety of EndeavorRxⓇ in adults with attention-deficit/hyperactivity disorder.

XNK Therapeutics AB announced that the company’s autologous natural killer cell therapy candidate XNK04 will be evaluated in combination with an ADCC competent PD-L1 inhibitor in liver cancer under a research agreement with a global pharma company.

Mekonos, Inc. has announced a new research collaboration with bit.bio, a synthetic biology company providing human cells for research, drug discovery and cell therapy.

Alvotech, a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced the initiation of Alvotech’s confirmatory patient study for AVT05, a biosimilar candidate to Simponi® and Simponi Aria®.

Medigene AG, an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, presents the webtool Expitope 3.0 at the 20th Annual Meeting of the Association for Cancer Immunotherapy, taking place May 3-5, 2023, in Mainz, Germany.

X4 Pharmaceuticals reported financial results for the first quarter ended March 31, 2023 and highlighted key upcoming expected milestones.